Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

(2005): Mahe E+, Transplantation 79(4), 476 (26%)
Fungal dermatitis (3–20%)
Hidradenitis
(2005): Mahe E+, Transplantation 79(4), 476 (12%)
Hypertrophy (3–20%)
Peripheral edema (54–64%)
Pruritus (3–20%)
(2002): Gladstone GC, Worcester, MA (personal
correspondence)
Purpura (3–20%)
(2002): Hardinger KL+, Transplantation 74(5), 739
Rash (sic) (10–20%)
(2000): Vasquez EM, Am J Health Syst Pharm 57, 437
Scrotal edema
Ulcerations (3–20%)
Vasculitis
(2005): Nagarajan S+, Pediatr Transplant 9(1), 97
(2002): Hardinger KL+, Transplantation 74(5), 739
Mucosal
Aphthous stomatitis (9%)
(2005): Mahe E+, Transplantation 79(4), 476 (60%)
(2001): Reitamo S+, Br J Dermatol 145(3), 438 (9%) (with
cyclosporine)
Gingival hyperplasia/hypertrophy (3–20%)
Gingivitis (3–20%)
(2005): Mahe E+, Transplantation 79(4), 476 (20%)
Oral candidiasis (3–20%)
Oral ulceration (3–20%)
(2005): Kuypers DR, Drug Saf 28(2), 153
(2004): Montalbano M+, Transplantation 78(2), 264 (24%)
(2003): Fairbanks KD+, Liver Transpl 9(10), 1079
Stomatitis (3–20%)
Hair
Hair – hirsutism (3–20%)
Nails
Nails – onychopathy
(2006): Mahe E+, Ann Dermatol Venereol 133(6-7), 531
(2005): Mahe E+, Transplantation 79(4), 476 (74%)
Nails – periungual infections
(2005): Mahe E+, Transplantation 79(4), 476 (16%)
Eyes
Eyelid edema (40%)
(2001): Mohaupt MG+, Transplantation 72(1), 162 (40%)
Other
Abdominal pain
(2005): Nagarajan S+, Pediatr Transplant 9(1), 97
Chills (3–20%)
Cough
(2006): Champion L+, AnnInternMed144(7), 505 (23 cases)
Death
(2007): Burzotta F+, Am J Cardiol 99(3), 364 (1 case)
Fever
(2006): Champion L+, AnnInternMed144(7), 505 (16 cases)
Hepatotoxicity
(2004): Neff GW+, Ann Pharmacother 38(10), 1593
Hot flashes
(2001): Reitamo S+, Br J Dermatol 145(3), 438 (12%) (with
cyclosporine)
Infections
(2002): Prescrire Int 11(62), 165
Myalgia/Myositis/Myopathy/Myotoxicity
(2003): Josef F+, Transplantation 76(12), 1773
Nephrotoxicity
(2007): Cho ME+, Am J Kidney Dis 49(2), 310
(2006): Pallet N+, Nephrol Ther 2(4), 183
Serum sickness (from stent)
(2007): Rana JS+, Ann Allergy Asthma Immunol 98(2), 201
Thrombophlebitis (3–20%)
Thrombosis
(2007): Kastrati A+, NEnglJMed356(10), 1030
(2004): Montalbano M+, Transplantation 78(2), 264
Upper respiratory infection (20–26%)
SITAXENTAN
Synonym: Sitaxsentan
Trade name: Thelin (Encysize)
Indications: Pulmonary arterial hypertension
Half-life: 10 hours
Clinically important, potentially hazardous interactions
with: warfarin
Reactions
Skin
Peripheral edema (9%)
(2005): Widlitz AC+, Expert Rev Cardiovasc Ther 3(6), 985
Other
Abdominal pain (>2%)
Hepatotoxicity
(2007): Benza RL+, J Heart Lung Transplant 26(1), 63
(2007): Wittbrodt ET+, Ann Pharmacother 41(1), 100
Myalgia/Myositis/Myopathy/Myotoxicity (>2%)
SMALLPOX VACCINE
SMALLPOX VACCINE 499
Trade name: Dryvax (Wyeth)
Indications: Prevention of smallpox (variola)
Category: Vaccine
Half-life: ~5 years
Clinically important, potentially hazardous interactions
with: corticosteroids
Reactions
Skin
Acne
Allergic reactions (sic)
Basal cell carcinoma
(1988): Ribeiro R+, Med Cutan Ibero Lat Am 16(2), 137
Bullous dermatitis
Carcinoma
(1980): Gecht ML, JAMA 244(15), 1675
Dermatitis
(2004): Gaertner EM+, Arch Pathol Lab Med 128(10), 1173
(2004): Greenberg RN+, Clin Infect Dis 38(7), 958
Dermatofibrosarcoma protuberans
(2003): Green JJ+, JAmAcadDermatol48, S54 (in scar)
Eczema
(2003): Wharton M+, MMWR Recomm Rep 52(RR-7), 1
Eczema vaccinatum
Erythema
(2004): Greenberg RN+, Clin Infect Dis 38(7), 958
Erythema multiforme
(2004): Chopra A+, Mayo Clin Proc 79(9), 1193
Erythema nodosum